Modality
Bispecific Ab
MOA
STINGag
Target
TIGIT
Pathway
Incretin
LNPNHParkinson's
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
~Jun 2022
→ ~Sep 2023
Phase 2
~Dec 2023
→ ~Mar 2025
Phase 3
Jun 2025
→ Feb 2028
Phase 3Current
NCT08885208
2,704 pts·PNH
2025-06→2028-02·Recruiting
2,704 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-211.9y awayPh3 Readout· PNH
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028
P3
Recruit…
Catalysts
Ph3 Readout
2028-02-21 · 1.9y away
PNH
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08885208 | Phase 3 | PNH | Recruiting | 2704 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| RHH-5389 | Roche | Preclinical | RET | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT |